Galmed Pharmaceuticals LtdNASDAQ:GLMDNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6600
- TODAY'S CHANGE (%)0.0900 (15.7895%)
- Bid / Lots0.6600/ 53
- Ask / Lots0.6799/ 2
- Open / Previous Close0.5825 / 0.5700
- Day Range
- 52 Week Range
- Volume37,582
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GLMD |
|---|---|---|
| 09:32 ET | 1158 | 0.6499 |
| 09:33 ET | 100 | 0.6499 |
| 09:37 ET | 500 | 0.65 |
| 09:39 ET | 300 | 0.65 |
| 09:50 ET | 100 | 0.6897 |
| 09:51 ET | 1600 | 0.67 |
| 09:53 ET | 17021 | 0.6501 |
| 09:55 ET | 4200 | 0.65 |
| 10:08 ET | 1391 | 0.69 |
| 10:29 ET | 3220 | 0.66 |
| 10:36 ET | 400 | 0.6822 |
| 10:44 ET | 153 | 0.6799 |
| 10:47 ET | 153 | 0.6601 |
| 11:30 ET | 1500 | 0.66995 |
| 11:34 ET | 3420 | 0.66 |
Jan 4, 2023
Galmed Pharmaceuticals Says Open-label Part of Phase 3 Aramchol Shows Fibrosis Improvement in Nonalcoholic Steatohepatitis Patients, from 2:16PM ET on Wednesday Jan 04, 2023 by MT Newswires
2:16PM ET on Wednesday Jan 04, 2023 by MT NewswiresBRIEF-Galmed Reports Results From The Open-Label Part Of The Armor Study Showing Improvements In Histology, Imaging, And Biomarkers With Aramchol, from 8:23AM ET on Wednesday Jan 04, 2023 by Thomson Reuters
8:23AM ET on Wednesday Jan 04, 2023 by Thomson ReutersGalmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol, from 8:00AM ET on Wednesday Jan 04, 2023 by PR Newswire
8:00AM ET on Wednesday Jan 04, 2023 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Galmed Pharmaceuticals Ltd | 14.4M | -0.7x | --- |
Theriva Biologics Inc | 14.4M | -0.7x | --- |
Avail Scientific Inc | 14.3M | -2.5x | --- |
CeCors Inc | 14.6M | 0.0x | --- |
Graybug Vision Inc | 14.1M | -0.4x | --- |
Cell Source Inc | 14.1M | -2.4x | --- |
Company Information
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Contact Information
- Headquarters
- 16 Ze'ev Tyomkin St. (4Th Fl.)TEL AVIV-YAFO, Israel 6578317
- Phone
- ---
- Fax
- ---
Executives
- President, Chief Executive Officer, Director
- Allen Baharaff
- Chief Financial Officer
- Doron Cohen
- Chief Operating Officer, Data Protection Officer
- Guy Nehemya
- Chief Accounting Officer
- Yohai Stenzler
- Chief Scientific Officer
- Liat Hayardeny
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.13 |
EPS | $-0.90 |
Book Value | $1.22 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
